DH DHR Danaher Corporation Loading... : Investor Sentiment and Bull/Bear Views

AI can now model cells, organs, tissue, and disease biology at scale and screen molecules computationally, shifting drug discovery from expensive trial-and-error toward data-driven target selection. Rather than picking which drug company wins, Ben prefers the tools that measure, test, collect, create, and sequence biological data, citing a basket including Danaher, Thermo Fisher, Schrödinger, Illumina, Guardant Health, and Twist Bioscience.

Fastest-growing AI harness/vertical AI companies are trading at 100-150x current ARR, an enormous multiple at scale, sometimes supported by low gross margins. By contrast, legacy software companies retain revenue extremely well and trade at low multiples, creating a multiple-arbitrage opportunity for holding companies such as Constellation Software and Danaher to buy them.

Danaher (DHR) was the consensus buy of the quarter, purchased by 8 different well-known value managers. When multiple elite value managers independently accumulate a stock in the same quarter, it often signals a strong fundamental undervaluation or a flight to quality. Following the smart money consensus into high-quality healthcare names like DHR offers a high-probability value play. 13F filings are delayed by up to 45 days; the managers' entry prices may be significantly lower than current market prices.